Almac Completes A Multi-Million-Pound Investment Enhancing Cold Chain Capabilities In Craigavon

Almac Clinical Services, part of the Almac Group, has completed a multi-million-pound investment to enhance cold chain capabilities at its global headquarters in Craigavon, Northern Ireland.

This strategic investment includes the completion of a purpose-built Ultra-Low Temperature facility which has tripled Almac Clinical Services’ -15°C to -25°C secondary packaging capabilities and doubled ultra-low temperature storage capacity (-60°C to -80°C) in Craigavon.

This investment is part of Almac’s global ongoing programme to expand Ultra-Low capabilities, including North Carolina and Singapore facilities which have already been completed.

Almac has also expanded its cold chain packaging capabilities and increased capacity by more than 60% in the Craigavon facility. The recent developments include an upgraded cold chain management centre with additional 2°C to 8°C secondary production rooms; new label printing and checking suites and new packaging design facilities.

This investment significantly expands the company’s global clinical supply to support biopharmaceutical products and will meet growing demand for Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapies, which require ultra-precise cold chain logistics to maintain product viability and compliance.

Dr Robert Dunlop, President and Managing Director of Almac Clinical Services said: “Almac is committed to supporting trial sponsors around the world to champion innovation and advance human health.

As the number of biological products in clinical development continues to grow, it is important that Almac can offer both the capability and capacity that clients will require in the future. The expansion of our existing Cold Chain management centre in Craigavon offers a prime solution to many of the manufacturing and supply chain challenges that impact the success of clinical trials.

“Combined, we’re proud to provide strict GMP environments, robust cold chain logistics and quality control through our state-of-the-art, ultra-low, temperature-controlled storage and production capability. This enables sponsors to deliver compliant and cost-effective packaging and labelling of biological IMPs and keep patient supply at the heart of our operations.

“These investments are a testament to our strategic vision to stay ahead of industry needs. By expanding our infrastructure and capabilities, we are ensuring that Almac remains a trusted partner in the evolving landscape of clinical trials.”

About Almac Clinical Services
The most comprehensive Global Clinical Supply Chain Solution in the marketplace.

Almac Clinical Services has over 30 years’ experience deploying clinical supply chain expertise and a full suite of end-to-end clinical solutions to over 600 Pharmaceutical and Biotech companies worldwide.

Guided by extensive clinical supply experience and expertise, Almac Clinical Services is recognised as one of the leading, multi-faceted, global solution providers within the niche and complex market of clinical trial supply.

About Almac Group
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.

Almac is a privately owned organisation which has grown organically, now employing more than 7,700 highly skilled personnel across 18 facilities including Europe, the USA and Asia.

For more information, visit almacgroup.com.